ReFlow Medical, Inc.

VIVA24: Late-Breaking Trials Highlight Advances in Vascular Intervention

7 months ago

• The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients. • DETOUR2 study reveals the durability of percutaneous transmural arterial bypass with the DETOUR System for complex femoropopliteal disease, showing promising 3-year outcomes. • SIRONA trial's post-hoc analysis suggests sirolimus-coated balloons as a viable alternative to paclitaxel-coated balloons in femoropopliteal angioplasty. • ELEGANCE registry indicates that drug-eluting devices in endovascular PAD treatment yield excellent 1-year outcomes in underrepresented patient groups.

VIVA24: Late-Breaking Trials Highlight Advances in Peripheral Artery Disease Treatment

7 months ago

• The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients. • DETOUR2 study shows percutaneous transmural arterial bypass with the DETOUR System offers durable outcomes for complex femoropopliteal lesions at three years. • The LIFE-BTK trial indicates the Global Limb Anatomic Staging System (GLASS) effectively identifies CLTI patients at higher risk for adverse events.